Medicine
Drax Exametazime 0.5 mg powder for injection
Drax Exametazime 0.5 mg powder for injection is a prescription medicine containing Technetium tc-99m exametazime for intravenous use, marketed by Jubilant Radiopharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store Drax Exametazime kit at 15°C - 25°C (59°F - 77°F). Store and dispose of…
Key facts
- Active ingredient (INN)
- Technetium tc-99m exametazime
- Brand
- Drax Exametazime
- Strength
- 0.5 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 5 vials
- Marketing authorisation holder
- Jubilant Radiopharma
- Manufacturer
- Jubilant RadiopharmaIndia
- Origin register
- US FDA, United States
- Storage
- Store Drax Exametazime kit at 15°C - 25°C (59°F - 77°F). Store and dispose of technetium Tc 99m exametazime in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V09AA01 Technetium tc-99m exametazime
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 August 2017
- Identifiers
- DailyMed set ID fa7811f9-2803-4126-8037-8f3e56462f9cNDC 65174-200Application NDA208870
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial | 65174-200-05 | Jubilant RadiopharmaIndia | 17 August 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Technetium tc-99m exametazime
Clinical summary
Technetium tc-99m exametazime is a radioactive diagnostic agent indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. MedsAcross supplies Technetium tc-99m exametazime for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Technetium tc-99m exametazimeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Drax Exametazime prescribing information (Jubilant Radiopharma) · U.S. National Library of Medicine, DailyMed
Need Drax Exametazime 0.5 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.